The role of cellular immunity in the pathogenesis and treatment of patients with primary liver cancer.

Abstract

e14519 Background: The issues of etiogenesis and pathogenesis of Primary Liver Cancer have not been fully understood so far. The arsenal of medications for treatment of this disease has also been scarce. It is well known that certain percentage of Primary Liver Cancer is caused by Viral Hepatitis (B,C) and intoxication by Alfatoxins, but percentage of Primary Liver Cancer that is not associated with the above factors is not so low. Methods: The goal of our research was to study the results of cellular immunity activation in treatment of advanced cases of Primary Liver Cancer. 22 patients with advanced stages of Primary Liver Cancer which were not associated with viral hepatitis were used for observation. The patients received treatment according to the protocol of Doxorubicin and Cyclophosphamide combined therapy. In order to activate the cellular immunity we utilized Phytohaemagglutinin. The above substance (solution) were given to the patients according to the certain dosage regimen and the previously selected schedule (per os) for 3 months. The control group comprised of 15 patients with the advanced form of liver cancer which received treatment only by Doxorubicin and Cyclophosphamide combined therapy protocol. The values of the cellular immunity were assessed by means of Immuno-cyto-chemical research of blood lymphocytes: CD3+, CD4+ and CD8+ quantitative indicators of the cells. Results: The results of the study have shown that: a) before treatment, the cellular immunity of all the patients was suppressed by equal index; b)in 3 months after treatment, cellular immunity of the observed patients increased by 29% against the control group (p < 0,001). Conclusions: With the results of the study, we can conclude that the activation of cellular immunity plays the essential role in the regimen of the combined therapy of Primary Liver Cancer. In addition, the positively expressed dynamics with the cellular immunity activation during the therapy indicates to the essential role in pathogenesis and its possible etiological role in initiation, promotion and progression of Primary Liver Cancer.